Want to join the conversation?
Biopharmaceutical company $AMGN and Brussels-based UCB announced positive top-line results for romosozumab from pivotal Phase 3 placebo-controlled study evaluating efficacy and safety of romosozumab in treating men with osteoporosis (BRIDGE study). Study met primary endpoint, showing increase in bone mineral density at lumbar spine.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.